Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study
Objective: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Methods: Patients with type IIIa and...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Asian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388221000874 |
| _version_ | 1818188576107528192 |
|---|---|
| author | Fabrizio Presicce Francesco Barrese Andrea Cantiani Alessio Filianoti Domenico Tuzzolo Paolo Di Palma Stefano Lauretti Stefano Brunori Marco Martini |
| author_facet | Fabrizio Presicce Francesco Barrese Andrea Cantiani Alessio Filianoti Domenico Tuzzolo Paolo Di Palma Stefano Lauretti Stefano Brunori Marco Martini |
| author_sort | Fabrizio Presicce |
| collection | DOAJ |
| description | Objective: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Methods: Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months. Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Scores (IPSS), International Index of Erectile Function (IIEF), four-glass test, uroflowmetry, and prostate-specific antigen assessments at baseline and at Week 4, and Week 12. Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score. Secondary outcomes included improvement of micturition and quality of life (QoL) domains of NIH-CPSI questionnaire. Results: A total of 61 males were enrolled. No adverse events were reported. Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score (mean difference: −9.2; p<0.01), NIH-CPSI pain domain (mean difference: −5.5; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score (mean difference: −5.6; p<0.01). No significant changes from baseline in terms of IIEF score or maximum flow rate were observed. At final follow-up (Day 90), further significant improvements in terms of NIH-CPSI total score (mean difference: −12.2; p<0.01), NIH-CPSI pain domain (mean difference: −6.6; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score were reported. Conclusion: Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS. |
| first_indexed | 2024-12-11T23:29:07Z |
| format | Article |
| id | doaj.art-7d0c043a88bd4c63bb3c3e39fd2dd7f7 |
| institution | Directory Open Access Journal |
| issn | 2214-3882 |
| language | English |
| last_indexed | 2024-12-11T23:29:07Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj.art-7d0c043a88bd4c63bb3c3e39fd2dd7f72022-12-22T00:46:06ZengElsevierAsian Journal of Urology2214-38822022-04-0192139145Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter studyFabrizio Presicce0Francesco Barrese1Andrea Cantiani2Alessio Filianoti3Domenico Tuzzolo4Paolo Di Palma5Stefano Lauretti6Stefano Brunori7Marco Martini8San Filippo Neri Hospital, Department of Urology, Rome, Italy; Corresponding author.San Filippo Neri Hospital, Department of Urology, Rome, ItalySant’Eugenio Hospital, Department of Urology, Rome, ItalySan Filippo Neri Hospital, Department of Urology, Rome, ItalyCasa del Sole Clinic, Department of Urology, Formia, ItalyFabrizio Spaziani Hospital, Department of Urology, Frosinone, ItalySanta Caterina della Rosa Clinic, Department of Urology, Rome, ItalyVilla Stuart Clinic, Department of Urology, Rome, ItalySan Filippo Neri Hospital, Department of Urology, Rome, ItalyObjective: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Methods: Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months. Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Scores (IPSS), International Index of Erectile Function (IIEF), four-glass test, uroflowmetry, and prostate-specific antigen assessments at baseline and at Week 4, and Week 12. Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score. Secondary outcomes included improvement of micturition and quality of life (QoL) domains of NIH-CPSI questionnaire. Results: A total of 61 males were enrolled. No adverse events were reported. Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score (mean difference: −9.2; p<0.01), NIH-CPSI pain domain (mean difference: −5.5; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score (mean difference: −5.6; p<0.01). No significant changes from baseline in terms of IIEF score or maximum flow rate were observed. At final follow-up (Day 90), further significant improvements in terms of NIH-CPSI total score (mean difference: −12.2; p<0.01), NIH-CPSI pain domain (mean difference: −6.6; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score were reported. Conclusion: Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS.http://www.sciencedirect.com/science/article/pii/S2214388221000874Boswellia serrataChronic prostatitisChronic pelvic pain syndromePropolisTreatment |
| spellingShingle | Fabrizio Presicce Francesco Barrese Andrea Cantiani Alessio Filianoti Domenico Tuzzolo Paolo Di Palma Stefano Lauretti Stefano Brunori Marco Martini Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study Asian Journal of Urology Boswellia serrata Chronic prostatitis Chronic pelvic pain syndrome Propolis Treatment |
| title | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
| title_full | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
| title_fullStr | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
| title_full_unstemmed | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
| title_short | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
| title_sort | boswellia resin extract and propolis derived polyphenols in patients with type iii chronic prostatitis chronic pelvic pain syndrome an italian prospective multicenter study |
| topic | Boswellia serrata Chronic prostatitis Chronic pelvic pain syndrome Propolis Treatment |
| url | http://www.sciencedirect.com/science/article/pii/S2214388221000874 |
| work_keys_str_mv | AT fabriziopresicce boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT francescobarrese boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT andreacantiani boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT alessiofilianoti boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT domenicotuzzolo boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT paolodipalma boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT stefanolauretti boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT stefanobrunori boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT marcomartini boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy |